75 related articles for article (PubMed ID: 25384872)
21. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
22. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Andreasen N; Blennow K
Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
[TBL] [Abstract][Full Text] [Related]
23. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
24. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
26. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
Mollenhauer B; Trenkwalder C; von Ahsen N; Bibl M; Steinacker P; Brechlin P; Schindehuette J; Poser S; Wiltfang J; Otto M
Dement Geriatr Cogn Disord; 2006; 22(3):200-8. PubMed ID: 16899997
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
[TBL] [Abstract][Full Text] [Related]
29. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics.
Reiber H
Restor Neurol Neurosci; 2003; 21(3-4):79-96. PubMed ID: 14530572
[TBL] [Abstract][Full Text] [Related]
30. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
Olsson B; Hertze J; Ohlsson M; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Zetterberg H; Blennow K; Hansson O
J Alzheimers Dis; 2013; 34(3):673-9. PubMed ID: 23254629
[TBL] [Abstract][Full Text] [Related]
32. The relationship between cerebrospinal fluid biomarkers and depression in elderly women.
Gudmundsson P; Skoog I; Waern M; Blennow K; Pálsson S; Rosengren L; Gustafson D
Am J Geriatr Psychiatry; 2007 Oct; 15(10):832-8. PubMed ID: 17911361
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.
Parnetti L; Lanari A; Saggese E; Spaccatini C; Gallai V
Neurol Sci; 2003 Oct; 24(3):199-200. PubMed ID: 14598086
[TBL] [Abstract][Full Text] [Related]
34. Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease.
Maetzler W; Stoycheva V; Schmid B; Schulte C; Hauser AK; Brockmann K; Melms A; Gasser T; Berg D
J Alzheimers Dis; 2010; 22(3):933-8. PubMed ID: 20858953
[TBL] [Abstract][Full Text] [Related]
35. [CSF-analyses in clinical diagnosis of Creutzfeldt-Jakob disease. A literature review and three cases from routine clinical practice].
Blennow K; Lind B; Andersson E; Andreasen N
Lakartidningen; 2001 May; 98(20):2446-51. PubMed ID: 11433975
[TBL] [Abstract][Full Text] [Related]
36. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
Engelborghs S; Le Bastard N
J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
[TBL] [Abstract][Full Text] [Related]
37. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
[TBL] [Abstract][Full Text] [Related]
38. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.
Verbeek MM; De Jong D; Kremer HP
Ann Clin Biochem; 2003 Jan; 40(Pt 1):25-40. PubMed ID: 12542908
[TBL] [Abstract][Full Text] [Related]
39. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
